FDA Approves First Generic Versions Of Pfizer Anti-Inflammatory Drug Celebrex

The Food and Drug Administration May 30 approved the first generic versions of Pfizer Inc.'s Celebrex (celecoxib) capsules for rheumatoid arthritis, osteoarthritis, short-term (acute) pain and other conditions.

Teva Pharmaceutical Industries Ltd., based in Israel, received approval to market celecoxib capsules in 50 mg, 100 mg, 200 mg and 400 mg strengths, and has 180-day exclusivity on the 100 mg, 200 mg and 400 mg products, the agency said. Mylan Pharmaceuticals Inc., which is based in Pittsburgh, received approval to market 50 mg celecoxib capsules.

“It is important for patients to have access to affordable treatment options for chronic conditions,” ...